Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025
Fortrea (FTRE) è stata riconosciuta come "Leader" nella valutazione Pharmacovigilance Operations PEAK Matrix® 2025 di Everest Group, apprezzata sia per le operazioni di farmacovigilanza pre- che post-approvazione. La valutazione ha analizzato 29 fornitori di servizi PV basandosi su impatto di mercato, visione e capacità. Le soluzioni di sicurezza end-to-end di Fortrea coprono tutte le fasi, dalle prime fasi cliniche fino al post-approvazione, supportate da professionisti dedicati che utilizzano sistemi di sicurezza standard del settore e automazioni proprietarie.
I servizi completi dell’azienda includono centro di contatto medico, gestione dei casi, revisione medica, reporting aggregato, sorveglianza della sicurezza e supporto QPPV. I punti di forza di Fortrea sono stati evidenziati nella profondità scientifica, scalabilità e presenza globale, con competenze in oltre 60 aree terapeutiche. Questo riconoscimento sottolinea il loro impegno a portare trattamenti innovativi ai pazienti più rapidamente, mantenendo alti standard di sicurezza.
Fortrea (FTRE) ha sido nombrada "Líder" en la evaluación Pharmacovigilance Operations PEAK Matrix® 2025 de Everest Group, reconocida tanto por sus operaciones de farmacovigilancia pre como post-aprobación. La evaluación consideró a 29 proveedores de operaciones PV, basándose en impacto de mercado, visión y capacidad. Las soluciones globales de seguridad de Fortrea cubren desde las fases clínicas tempranas hasta el post-aprobación, apoyadas por profesionales dedicados que emplean sistemas de seguridad estándar de la industria y automatización propia.
Los servicios integrales de la compañía incluyen centro de contacto médico, procesamiento de casos, revisión médica, reportes agregados, vigilancia de seguridad y soporte QPPV. Las fortalezas de Fortrea se destacaron en profundidad científica, escalabilidad y alcance global, con experiencia en más de 60 áreas terapéuticas. Este reconocimiento resalta su compromiso por ofrecer tratamientos que cambian vidas a los pacientes más rápido, manteniendo altos estándares de seguridad.
Fortrea (FTRE)는 Everest Group의 2025년 Pharmacovigilance Operations PEAK Matrix® 평가에서 '리더'로 선정되었으며, 승인 전후 약물감시 운영 모두에서 인정받았습니다. 이번 평가는 시장 영향력, 비전, 역량을 기준으로 29개의 PV 운영 제공업체를 평가했습니다. Fortrea의 글로벌 종합 안전 솔루션은 초기 임상 단계부터 승인 후까지 전 범위를 아우르며, 업계 표준 안전 시스템과 자체 자동화를 활용하는 전담 전문가들이 지원합니다.
회사의 포괄적인 서비스에는 의료 연락 센터, 사례 처리, 의료 검토, 종합 보고, 안전 감시 및 QPPV 지원이 포함됩니다. Fortrea의 강점은 과학적 깊이, 확장성, 글로벌 범위에서 두드러졌으며, 60개 이상의 치료 분야에 걸친 전문성을 보유하고 있습니다. 이 인정은 고품질 안전 기준을 유지하면서 환자에게 혁신적인 치료를 더 빠르게 제공하려는 그들의 노력을 강조합니다.
Fortrea (FTRE) a été désignée "Leader" dans l’évaluation Pharmacovigilance Operations PEAK Matrix® 2025 d’Everest Group, reconnue pour ses opérations de pharmacovigilance avant et après approbation. L’évaluation a porté sur 29 prestataires d’opérations PV, en se basant sur l’impact sur le marché, la vision et les capacités. Les solutions globales de sécurité de Fortrea couvrent toutes les étapes, des phases cliniques précoces jusqu’après approbation, soutenues par des professionnels dédiés utilisant des systèmes de sécurité standards du secteur et une automatisation propriétaire.
Les services complets de l’entreprise incluent un centre de contact médical, le traitement des cas, la revue médicale, le reporting agrégé, la surveillance de la sécurité et le support QPPV. Les points forts de Fortrea résident dans la profondeur scientifique, l’évolutivité et la portée mondiale, avec une expertise dans plus de 60 domaines thérapeutiques. Cette reconnaissance souligne leur engagement à apporter plus rapidement des traitements qui changent la vie des patients, tout en maintenant des standards élevés de sécurité.
Fortrea (FTRE) wurde im Everest Group Pharmacovigilance Operations PEAK Matrix® Assessment 2025 als „Leader“ eingestuft und für seine Pharmakovigilanz-Operationen vor und nach der Zulassung anerkannt. Die Bewertung umfasste 29 PV-Anbieter und basierte auf Markteinfluss, Vision und Fähigkeiten. Fortreas globale End-to-End-Sicherheitslösungen erstrecken sich von den frühen klinischen Phasen bis zur Nachzulassung, unterstützt von spezialisierten Fachkräften, die branchenübliche Sicherheitssysteme und proprietäre Automatisierung einsetzen.
Das umfassende Dienstleistungsangebot des Unternehmens umfasst medizinisches Kontaktcenter, Fallbearbeitung, medizinische Prüfung, aggregierte Berichterstattung, Sicherheitsüberwachung und QPPV-Unterstützung. Fortreas Stärken liegen in wissenschaftlicher Tiefe, Skalierbarkeit und globaler Reichweite mit Expertise in über 60 therapeutischen Bereichen. Diese Auszeichnung unterstreicht ihr Engagement, lebensverändernde Behandlungen schneller zu den Patienten zu bringen und dabei hohe Sicherheitsstandards einzuhalten.
- Recognition as a Leader in both pre-and post-approval pharmacovigilance operations
- Comprehensive coverage across 60+ therapeutic areas showing broad expertise
- Strong client feedback on solutions and service delivery
- Global operational capability with QPPV coverage and technology-led innovation
- None.
Recognized in both pre-and post-approval pharmacovigilance operations
DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assesses market impact along with vision and capability.
“Fortrea’s mission is to bring life-changing treatments to patients faster, and we have translated our profound commitment to patients into recognized leadership in pharmacovigilance,” said Mark Morais, chief operations officer and president, Fortrea Clinical Development. “Fortrea provides global end-to-end safety solutions that span the life cycle of products from early clinical phases through post-approval. Our first-time-right approach prioritizes the needs of patients, physicians and regulatory authorities. Our customers have given us great feedback on our solutions and earning this industry recognition is a further testament to our dedicated teams.”
In the Everest Group report, it assessed 29 PV operations providers featured on the PV Operations PEAK Matrix. Each provider profile provided a holistic picture of its service focus, solution offerings, and domain investments. The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and an ongoing analysis of the PV operations market.
“As pharmacovigilance adapts to greater therapeutic complexity, heightened regulatory scrutiny, and increasing patient safety expectations, sponsors are turning to service provider partners that go beyond transactional delivery, seeking those who offer integrated scientific insight, forward-looking risk mitigation, and end-to-end strategic support across the product lifecycle,” said Vandana Sharma, practice director at Everest Group. “Fortrea stands out with its dual-strength PV capabilities, offering comprehensive clinical-stage safety services built on deep domain expertise across 60+ therapeutic areas, alongside robust post-marketing operations supported by global Qualified Person Responsible for Pharmacovigilance (QPPV) coverage and technology-led innovation. Its multidisciplinary collaboration model, flexible delivery frameworks, and sustained investment in technology and partnerships across key PV functions set it apart in the market. Clients consistently recognize Fortrea’s strengths in scientific depth, scalability, and global reach, earning it a Leader position in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025.”
Fortrea’s safety team comprises dedicated, globally based professionals, using industry-standard safety systems and proprietary automation to maximize efficiencies and address country-specific requirements. Its safety offerings include a medical contact center; case processing; medical review; aggregate reporting; safety surveillance; and QPPV support. For more information, please visit: https://www.fortrea.com/clinical-solutions/safety.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.
Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
FAQ
What recognition did Fortrea (FTRE) receive in the Everest Group's 2025 assessment?
How many therapeutic areas does Fortrea's pharmacovigilance service cover?
What key services does Fortrea's safety team provide?
How many PV operations providers were evaluated in the Everest Group assessment?
What are the main strengths highlighted in Fortrea's assessment by Everest Group?
